As compounding pharmacists, we’re often on the front lines when patients and providers start exploring emerging therapies — especially those that live in the grey space between hopeful promise and clinical validation. The recent PCCA webinar on Mebendazole and Ivermectin in Oncology addressed just that. If you missed it, here are the key takeaways, insights and cautionary notes from the session — tailored for your role behind the counter and in the consult room.

Why Mebendazole and Ivermectin?

Interest in repurposing these antiparasitic agents for oncology stems from both urgency and practicality. Drug development is notoriously slow and expensive — especially in oncology — so repurposing already-approved medications is a logical pursuit.¹

Mebendazole, in particular, has emerged as a compelling candidate due to its low toxicity profile and its potential to disrupt cancer cell mitosis via microtubule inhibition. Similarly, ivermectin has shown promising anti-inflammatory and anticancer properties in preclinical models.

But with promise comes responsibility. Let’s break it down.

The Appeal of Mebendazole in Oncology

Potential Mechanism of Action

• Mebendazole exerts its antihelminthic activity by inhibiting microtubule formation — disrupting cell division and leading to cellular apoptosis.¹
• Other microtubule inhibitors, like paclitaxel and vincristine, are already used in oncology.²
• Unlike many microtubule inhibitors, mebendazole also targets the colchicine binding site, potentially overcoming resistance mechanisms like P-glycoprotein expression.^3,4

Preclinical Data Highlights

• Numerous cell-line studies demonstrate synergy with standard chemotherapeutics like paclitaxel and docetaxel. ^5,6
• Shows potential in enhancing radiation sensitivity and preventing metastasis via a reduction in cancer stemness.^7,8

Human Evidence (Still Early)

• Several case reports suggest possible disease stabilization and partial remissions, though it should be noted controlled clinical trials are needed.^9,10
• A phase I- maximum tolerable dose study in glioblastoma patients found that doses up to 200 mg/kg/day were well tolerated with minimal toxicity that was reversible upon dose reduction.¹¹
• A phase II trial in glioblastoma patients showed modest improvement in survival but not enough to move forward to phase III.¹²

Pharmacokinetics

• Low bioavailability (5–10%) that increases significantly when administered with a high-fat meal
• C_max 137.4 ng/mL at a dose of 10 mg/kg
• T_max 2–4 hours¹³

Formulation Matters

• Polymorph C of mebendazole has the best ability to cross the blood-brain barrier and the greatest potential.¹⁴
• It’s susceptible to conversion to less desirable polymorphs (A or B) with the addition of heat and moisture.¹⁵

What About Ivermectin?

Mechanism and Activity

• Inhibits glutamate-gated chloride channels (parasite-specific)¹⁶
• Has anti-inflammatory activity in rosacea via NF-kappa B inhibition¹⁷

Preclinical Promise

• Cell line studies show ivermectin targets multiple cancer-related pathways including Akt/mTOR and PAK1.¹⁷
• Proposed mechanism in triple-negative breast cancer (TNBC) is SIN3A inhibition — potentially turning “cold” tumors “hot.”^17,18

Clinical Use: Thin Data

• Mostly anecdotal reports and case series
• One case series reported improved symptoms and reduced tumor markers in 3 patients using ivermectin as part of a combination regimen of repurposed medications.¹⁹
• Long-term safety data in humans is limited.

Compounding and Dosing Considerations

Mebendazole

• Dosing in oncology may require significantly higher dosing than antihelmintic protocols.
• Avoid combining with metronidazole (risk of Stevens-Johnson Syndrome).
• Monitor LFTs and CBC.

Ivermectin

• Dosing for oncology is not yet well-defined.
• Not water soluble — anhydrous suspensions may be useful for patients who can’t take tablets.
• Interacts with idelalisib, an anticancer drug — always do a full med review.

Combination Products?

Mechanistically, mebendazole and ivermectin may complement one another, but their pharmacokinetics don’t align — making a combined formulation illogical. Separate dosing regimens are advised if used concurrently.

Regulatory Realities and Clinical Ethics

PCCA Vice President of Clinical Services Matt Martin, PharmD, BCSCP, reinforced that marketing around these agents must be handled with extreme care:

• Don’t overstate preclinical or anecdotal findings.
• Distinguish clearly between in vitro, in vivo and human data.
• Avoid claims about safety or efficacy, even indirectly — especially in marketing materials.

FDA’s essential copy guidance still applies. Even if a patient needs a high number of tablets, FDA expects use of the commercially available product unless there's a clinical necessity for a different strength, form or route (e.g., suspension for dysphagia).

Final Thoughts

There is real scientific interest in these agents, but the human data are early and limited. As pharmacists, our role is to provide evidence-based guidance and work closely with oncology teams when these agents are considered.

At PCCA, we’ll continue to share updates as new data emerge. Until then, remember:

• Preclinical promise ≠ clinical proof
• Formulation integrity matters — especially with polymorph-sensitive APIs.
• Regulatory caution isn’t optional — it’s a requirement.

Questions or compounding challenges? Reach out to PCCA’s Clinical Services team. We're here to help you navigate the science, safety and regulatory expectations.

Stay tuned for future webinars and ongoing resources from PCCA Clinical Services.

1. Guerini, Andrea Emanuele, et al. “Mebendazole as a Candidate for Drug Repurposing in Oncology: An Extensive Review of Current Literature.” Cancers, vol. 11, no. 9, 1 Sept. 2019, p. 1284, www.mdpi.com/2072-6694/11/9/1284, https://doi.org/10.3390/cancers11091284. Accessed 6 June 2025.
2. Perez, E. A. “Microtubule Inhibitors: Differentiating Tubulin-Inhibiting Agents Based on Mechanisms of Action, Clinical Activity, and Resistance.” Molecular Cancer Therapeutics, vol. 8, no. 8, 1 Aug. 2009, pp. 2086–2095, https://doi.org/10.1158/1535-7163.mct-09-0366.
3. Lee, Yeuan Ting, et al. “Benzimidazole and Its Derivatives as Cancer Therapeutics: The Potential Role from Traditional to Precision Medicine.” Acta Pharmaceutica Sinica B, vol. 13, no. 2, 21 Sept. 2022, www.sciencedirect.com/science/article/pii/S2211383522003999, https://doi.org/10.1016/j.apsb.2022.09.010.
4. McLoughlin, Eavan C., and Niamh M. O’Boyle. “Colchicine-Binding Site Inhibitors from Chemistry to Clinic: A Review.” Pharmaceuticals, vol. 13, no. 1, 1 Jan. 2020, p. 8, www.mdpi.com/1424-8247/13/1/8, https://doi.org/10.3390/ph13010008.
5. Zhang, Jie, and Yanyan Cui. “Synergistic Inhibition of Proliferation and Induction of Apoptosis in Oral Tongue Squamous Cell Carcinoma by Mebendazole and Paclitaxel via PI3K/AKT Pathway Mitigation.” Naunyn-Schmiedeberg’s Archives of Pharmacology, vol. 398, no. 5, 30 Nov. 2024, pp. 5881–5893, https://doi.org/10.1007/s00210-024-03670-y. Accessed 6 June 2025.
6. Rushworth, Linda K., et al. “Repurposing Screen Identifies Mebendazole as a Clinical Candidate to Synergise with Docetaxel for Prostate Cancer Treatment.” British Journal of Cancer, vol. 122, no. 4, 17 Dec. 2019, pp. 517–527, https://doi.org/10.1038/s41416-019-0681-5.
7. Tang, Jie-Yu, and Yun-Xi Peng. “USP5 Binds and Stabilizes EphA2 to Increase Nasopharyngeal Carcinoma Radioresistance.” International Journal of Biological Sciences, vol. 21, no. 3, June 2025, pp. 893–909, pubmed.ncbi.nlm.nih.gov/39897046/, https://doi.org/10.7150/ijbs.102461.
8. Joe, Natalie, and Inês Godet. “Mebendazole Prevents Distant Organ Metastases in Part by Decreasing ITGβ4 Expression and Cancer Stemness.” Breast Cancer Research, vol. 24, no. 1, 28 Dec. 2022, https://doi.org/10.1186/s13058-022-01591-3. Accessed 6 June 2025.
9. Dobrosotskaya, Irina Y., et al. “Mebendazole Monotherapy and Long-Term Disease Control in Metastatic Adrenocortical Carcinoma.” Endocrine Practice, vol. 17, no. 3, 1 May 2011, pp. e59–e62, www.sciencedirect.com/science/article/abs/pii/S1530891X20404434, https://doi.org/10.4158/EP10390.CR. Accessed 6 June 2025.
10. Nygren, Peter, and Rolf Larsson. “Drug Repositioning from Bench to Bedside: Tumour Remission by the Antihelmintic Drug Mebendazole in Refractory Metastatic Colon Cancer.” Acta Oncologica, vol. 53, no. 3, 28 Oct. 2013, pp. 427–428, https://doi.org/10.3109/0284186x.2013.844359. Accessed 6 June 2025.
11. Gallia, Gary L, et al. “Mebendazole and Temozolomide in Patients with Newly Diagnosed High-Grade Gliomas: Results of a Phase 1 Clinical Trial.” Neuro-Oncology Advances, vol. 3, no. 1, 1 Jan. 2021, https://doi.org/10.1093/noajnl/vdaa154. Accessed 6 June 2025.
12. Menon, Nandini Sharrel, et al. “Mebendazole in Recurrent Glioblastoma: Results of a Phase 2 Randomized Study.” Journal of Clinical Oncology, vol. 40, no. 16_suppl, 1 June 2022, pp. 2029–2029, https://doi.org/10.1200/jco.2022.40.16_suppl.2029. Accessed 6 June 2025.
13. Song, Bomi, et al. “Repurposing of Benzimidazole Anthelmintic Drugs as Cancer Therapeutics.” Cancers, vol. 14, no. 19, 22 Sept. 2022, p. 4601, https://doi.org/10.3390/cancers14194601.
14. Meco, Daniela, et al. “Emerging Perspectives on the Antiparasitic Mebendazole as a Repurposed Drug for the Treatment of Brain Cancers.” International Journal of Molecular Sciences, vol. 24, no. 2, 10 Jan. 2023, p. 1334, www.ncbi.nlm.nih.gov/pmc/articles/PMC9862092/, https://doi.org/10.3390/ijms24021334. Accessed 6 June 2025.
15. Calvo, Natalia L., et al. “Mebendazole Crystal Forms in Tablet Formulations. An ATR-FTIR/Chemometrics Approach to Polymorph Assignment.” Journal of Pharmaceutical and Biomedical Analysis, vol. 122, Apr. 2016, pp. 157–165, https://doi.org/10.1016/j.jpba.2016.01.035.
16. Tang, Mingyang, et al. “Ivermectin, a Potential Anticancer Drug Derived from an Antiparasitic Drug.” Pharmacological Research, vol. 163, 1 Jan. 2021, p. 105207, www.ncbi.nlm.nih.gov/pmc/articles/PMC7505114/, https://doi.org/10.1016/j.phrs.2020.105207. Accessed 6 June 2025.
17. Kaur, Baneet, et al. “Ivermectin: A Multifaceted Drug with a Potential beyond Anti-Parasitic Therapy.” Curēus, 12 Mar. 2024, www.ncbi.nlm.nih.gov/pmc/articles/PMC11008553/, https://doi.org/10.7759/cureus.56025. Accessed 6 June 2025.
18. Yeon Jin Kwon, et al. “Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer.” Molecular Cancer Therapeutics, vol. 14, no. 8, 1 Aug. 2015, pp. 1824–1836, https://doi.org/10.1158/1535-7163.mct-14-0980-t. Accessed 6 June 2025.
19. Ishiguro, Tatsuaki, et al. “Synergistic Anti-Tumor Effect of Dichloroacetate and Ivermectin.” Cureus, 3 Feb. 2022, https://doi.org/10.7759/cureus.21884. Accessed 6 June 2025.